Group 1 - Lazard Asset Management LLC reduced its holdings in China National Pharmaceutical Group (01099) by 546,400 shares at an average price of HKD 18.48 per share, totaling approximately HKD 10.0975 million [1] - After the reduction, Lazard's latest shareholding stands at approximately 134 million shares, representing a holding percentage of 9.99% [1]

| 股份代號: | 01099 | | --- | --- | | 上市法國名稱: | 國藥控股股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 29/08/2025 - 29/09/2025 | 格隆汇9月29日丨根据联交所最新权益披露资料显示，2025年9月23日，国药控股(01099.HK)遭FMR LLC在场内以每股均价18.4387港元减持131.88万股，涉 资约2431.7万港元。 减持后，FMR LLC最新持股数目为146,893,747股，持股比例由11.05%下降至10.95%。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 請參閱上述 * 註 | | | | | | | | ler 份百分比 年) | | | | | | | | (%) | | | CS20250926E00273 | FMR LLC 1,318, ...

香港联交所最新资料显示，9月23日，FMR LLC减持国药控股(01099)131.88万股，每股作价18.4387港 元，总金额约为2431.7万港元。减持后最新持股数目约为1.47亿股，持股比例为10.95%。 ...

智通财经APP获悉，香港联交所最新资料显示，9月23日，FMR LLC减持国药控股(01099)131.88万股， 每股作价18.4387港元，总金额约为2431.7万港元。减持后最新持股数目约为1.47亿股，持股比例为 10.95%。 ...

關愛 生命 呵護 健康 關愛 生命 健康 中期報告 2025 * 本公司以中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。 The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance * under its Chinese name and the English name "Sinopharm Group Co. Ltd.". All for Health for All 公司簡介 本公司是中國醫藥集團有限公司所屬核心企業，成立於2003年1月，於 2009年9月在香港聯交所上市（股票代碼：01099.HK），為中國藥品、醫 療器械及醫療保健產品龍頭分銷商和零售商，及領先的供應鏈服務提供 商。 本集團主營醫藥及醫療器械分銷業務，依託覆蓋全國的分銷及配送網絡，為 國內外藥品、醫療器械、耗材及其他醫療保健產品的製造商和供貨商，及下 游的醫院、其他分銷商、零售藥店、基層醫療機構等客戶提供全面的分銷、 配送和其他增值服務。 Health ...

Core Viewpoint - Despite the mid-term performance of leading Chinese pharmaceutical distributors not turning profitable by the first half of 2025, there is structural optimism in the industry due to several factors [1] Industry Summary - Potential relaxation of mainland medical insurance spending may occur [1] - Volume-based procurement may see optimization, influenced by potential anti-involution measures in the healthcare sector [1] - Enhanced cash payment capabilities of medical insurance funds are expected [1] - The domestic interest rate reduction cycle will assist distributors in improving financial leverage [1] Company Summary - Citic Securities raised the target price for China National Pharmaceutical Group (01099) by 22.5%, from HKD 20 to HKD 24.5 [1] - Shanghai Pharmaceuticals (02607) H-shares target price increased by 15.4%, from HKD 12.3 to HKD 14.2 [1] - Target price for China Resources Pharmaceutical (03320) was lowered by 5.1%, from HKD 5.9 to HKD 5.6 [1] - All three companies maintain an "outperform the market" rating, with China National Pharmaceutical Group being the preferred choice [1]

Group 1 - The core viewpoint of the article indicates a structural optimism for the pharmaceutical distribution industry in China despite the mid-term performance not turning profitable by the first half of 2025 [1] - Factors contributing to this optimism include potential relaxation of mainland medical insurance spending, possible optimization of volume-based procurement due to anti-involution measures in the healthcare sector, enhanced cash payment capabilities of medical insurance funds, and a domestic interest rate reduction cycle that may help distributors improve financial leverage [1] Group 2 - Citic Lyon raised the target price for China National Pharmaceutical Group (01099) by 22.5%, from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals (02607) H-shares was increased by 15.4%, from HKD 12.3 to HKD 14.2 [1] - However, the target price for China Resources Pharmaceutical (03320) was lowered by 5.1%, from HKD 5.9 to HKD 5.6 [1] - The rating for all the mentioned companies remains "outperform the market," with China National Pharmaceutical Group being the preferred choice [1]

Group 1 - Lazard Asset Management LLC increased its stake in China National Pharmaceutical Group (国药控股) by purchasing 636,800 shares at an average price of HKD 18.5992 per share, totaling approximately HKD 11.84 million [1] - Following this transaction, Lazard Asset Management LLC's total shareholding in China National Pharmaceutical Group rose to 134,544,253 shares, increasing its ownership percentage from 9.98% to 10.03% [1]

香港联交所最新资料显示，9月9日，Lazard Asset Management LLC增持国药控股(01099)63.68万股，每 股作价18.5992港元，总金额约为1184.4万港元。增持后最新持股数目约为1.35亿股，最新持股比例为 10.03%。 ...

智通财经APP获悉，香港联交所最新资料显示，9月9日，Lazard Asset Management LLC增持国药控股 (01099)63.68万股，每股作价18.5992港元，总金额约为1184.4万港元。增持后最新持股数目约为1.35亿 股，最新持股比例为10.03%。 ...